Stifel Nicolaus Issues Positive Forecast for Neurocrine Biosciences (NASDAQ:NBIX) Stock Price

Neurocrine Biosciences (NASDAQ:NBIX) had its price target hoisted by stock analysts at Stifel Nicolaus from $188.00 to $215.00 in a report released on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target indicates a potential upside of 28.90% from the company’s previous close.

NBIX has been the subject of a number of other reports. Guggenheim lifted their price target on shares of Neurocrine Biosciences from $200.00 to $222.00 and gave the stock a “buy” rating in a research note on Friday. Wedbush raised their target price on shares of Neurocrine Biosciences from $166.00 to $176.00 and gave the stock an “outperform” rating in a report on Wednesday, May 6th. Weiss Ratings raised shares of Neurocrine Biosciences from a “buy (b-)” rating to a “buy (b)” rating in a research report on Tuesday. Leerink Partners boosted their target price on shares of Neurocrine Biosciences from $160.00 to $170.00 and gave the company an “outperform” rating in a research note on Wednesday, April 22nd. Finally, Morgan Stanley raised their price target on Neurocrine Biosciences from $185.00 to $191.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $197.29.

Neurocrine Biosciences Price Performance

NBIX stock traded down $18.71 during trading on Friday, hitting $166.79. 804,441 shares of the stock traded hands, compared to its average volume of 1,176,510. The stock has a market cap of $16.77 billion, a price-to-earnings ratio of 25.62, a price-to-earnings-growth ratio of 0.76 and a beta of 0.39. Neurocrine Biosciences has a 1 year low of $122.14 and a 1 year high of $186.12. The firm’s 50 day moving average is $167.61 and its two-hundred day moving average is $146.25.

Insider Buying and Selling at Neurocrine Biosciences

In other Neurocrine Biosciences news, insider Darin Lippoldt sold 10,000 shares of the company’s stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $179.60, for a total value of $1,796,000.00. Following the completion of the sale, the insider owned 54,729 shares in the company, valued at $9,829,328.40. This represents a 15.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Leslie V. Norwalk sold 1,250 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $182.01, for a total value of $227,512.50. Following the completion of the transaction, the director directly owned 1,588 shares in the company, valued at $289,031.88. This trade represents a 44.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 395,422 shares of company stock worth $62,448,693. 4.60% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its holdings in Neurocrine Biosciences by 36.7% during the first quarter. Royal Bank of Canada now owns 82,810 shares of the company’s stock valued at $9,158,000 after purchasing an additional 22,224 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of Neurocrine Biosciences by 60.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 14,783 shares of the company’s stock worth $1,647,000 after purchasing an additional 5,577 shares in the last quarter. NewEdge Advisors LLC raised its position in shares of Neurocrine Biosciences by 56.3% during the 1st quarter. NewEdge Advisors LLC now owns 7,630 shares of the company’s stock valued at $844,000 after purchasing an additional 2,747 shares during the period. Empowered Funds LLC bought a new stake in shares of Neurocrine Biosciences during the 1st quarter valued at $1,333,000. Finally, Geneos Wealth Management Inc. lifted its stake in shares of Neurocrine Biosciences by 143.6% during the 1st quarter. Geneos Wealth Management Inc. now owns 229 shares of the company’s stock valued at $25,000 after buying an additional 135 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Key Neurocrine Biosciences News

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Neurocrine reported second-quarter revenue of $959 million, up approximately 39% year over year and above the roughly $891 million analyst consensus. Adjusted earnings were $2.85 per share, surpassing estimates ranging from $1.66 to $2.26 and rising sharply from the prior year. Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
• Positive Sentiment: The company raised 2026 net product-sales guidance for INGREZZA, its lead tardive-dyskinesia treatment, to $2.825 billion-$2.875 billion. INGREZZA sales increased 15% year over year to $716 million, while CRENESSITY contributed $184 million and newly acquired VYKAT XR generated $54 million after the Soleno Therapeutics acquisition closed in May. Neurocrine Biosciences Q2 Revenue Rises 39%
• Positive Sentiment: Analyst sentiment remains favorable, with several firms recently raising price targets between $195 and $221 and the shares carrying a consensus “Moderate Buy” rating. Neurocrine Biosciences Analyst and Trading Information
• Neutral Sentiment: Neurocrine ended the quarter with approximately $482 million in cash, cash equivalents and marketable securities. However, the quarter includes only a partial contribution from VYKAT XR following the Soleno acquisition, making integration and future product uptake important factors for investors.
• Negative Sentiment: Director Leslie Norwalk sold 1,250 shares worth approximately $227,500, reducing her ownership by 44%. The transaction was conducted under a pre-arranged Rule 10b5-1 plan, which lessens its significance, but broader disclosures show numerous insider sales and no reported open-market insider purchases in the past six months. Neurocrine Director Stock Sale

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.